Zuko Komisa
- South Africa has received its first shipment of 38 000 doses of Lenacapavir, a long-acting HIV prevention drug.
- The injectable medication is administered only twice a year, significantly improving ease of use and treatment adherence.
- This rollout supports the national target of ending AIDS as a public health threat by 2030 through targeted, phased implementation.
The Department of Health has confirmed the arrival of South Africa’s first batch of Lenacapavir, a groundbreaking HIV prevention medication.
Approximately 38 000 doses of the six-monthly injectable have landed in the country, representing a significant milestone in the national strategy to curb new infections.
This medication is expected to bolster prevention efforts by providing a more convenient alternative for those who find it difficult to access or maintain daily preventative methods.
By requiring only two injections per year, Lenacapavir is designed to improve adherence amongst high-risk and vulnerable groups, including young women and sex workers.
The introduction of this treatment is a key component of South Africa’s broader mission to eliminate AIDS as a public health threat by 2030.
The Department of Health is expected to announce an official launch date and a phased implementation plan in the coming weeks, detailing how the medication will be distributed across the country.
READ NEXT: ‘I don’t think I’ll ever recover’: Bacardi star breaks silence on abusive marriage and trauma
The post The first 38 000 doses have arrived: Could this shipment end the HIV epidemic? appeared first on KAYA 959.
